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The proportion of endometrial cancers associated with
Lynch syndrome: a systematic review of the literature
and meta-analysis
N. A. J. Ryan, MBChB 1,2, M. A. Glaire, MBChB3, D. Blake, MBChB4, M. Cabrera-Dandy, MBChB5,
D. G. Evans, MD2,6 and E. J. Crosbie, PhD 1,7
Purpose: Endometrial cancer (EC) is often the sentinel cancer in
women with Lynch syndrome (LS). However, efforts to implement
universal LS screening in EC patients have been hampered by a
lack of evidence detailing the proportion of EC patients that would
be expected to screen positive for LS.
Methods: Studies were identified by electronic searches of
Medline, Embase, Cochrane CENTRAL and Web of Science.
Proportions of test positivity were calculated by random and fixed-
effects meta-analysis models. I2 score was used to assess hetero-
geneity across studies.
Results: Fifty-three studies, including 12,633 EC patients, met the
inclusion criteria. The overall proportion of endometrial tumors
with microsatellite instability or mismatch repair (MMR) deficiency
by immunohistochemistry (IHC) was 0.27 (95% confidence interval
[CI] 0.25–0.28, I2: 71%) and 0.26 (95% CI 0.25–0.27, I2: 88%),
respectively. Of those women with abnormal tumor testing, 0.29
(95% CI 0.25–0.33, I2: 83%) had LS-associated pathogenic variants
on germline testing; therefore around 3% of ECs can be attributed
to LS. Preselection of EC cases did increase the proportion of
germline LS diagnoses.
Conclusion: The current study suggests that prevalence of LS in
EC patients is approximately 3%, similar to that of colorectal cancer
patients; therefore our data support the implementation of
universal EC screening for LS.
Genetics in Medicine (2019) 21:2167–2180; https://doi.org/10.1038/s41436-
019-0536-8
Keywords: systematic review; Lynch syndrome; endometrial
cancer; mismatch repair (MMR) immunohistochemistry; micro-
satellite instability (MSI)
INTRODUCTION
Lynch syndrome (LS) is an autosomal dominant cancer
predisposition syndrome. Those affected most commonly
inherit an inactivating variant in one of the four mismatch
repair system (MMR) genes: MLH1, MSH2, MSH6, or PMS2.
This highly conserved system is responsible for correcting
insertion and deletion errors that occur during genomic
replication.1 Loss of MMR functioning, termed MMR
deficiency (MMRd), leads to microsatellite instability
(MSI),2 a hypermutated phenotype, and increased cancer
susceptibility. LS patients are at an increased risk for a
number of different malignancies, but most commonly
develop colorectal and endometrial cancer.3,4 As a result,
patients with LS have a decreased life expectancy compared
with nonaffected individuals.5
Diagnosing LS in endometrial cancer (EC) patients is an
important step in clinical management. It allows for cascade
testing to diagnose family members who may also have
the disease.6 Furthermore, timely LS diagnosis allows for the
initiation of lifestyle modification such as weight loss,
chemoprophylaxis, and cancer site surveillance to prevent
the development of further LS-related malignancies, most
notably colorectal cancer (CRC).4,7 Annual colonoscopy has
been shown to improve overall survival in LS patients through
the detection and removal of adenomatous polyps.4 There is a
growing drive for universal screening of CRC patients for
LS.8–10 Indeed, the National Institute of Health and Care
Excellence (NICE) in the United Kingdom has recently
introduced a LS screening pathway for all CRC patients,
alongside numerous institutions in the United States.11 LS
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screening pathways utilize tumor-based testing (immunohis-
tochemistry [IHC] for MMR protein loss, MSI testing or
MLH1 promoter methylation testing) to triage cases to
undergo germline testing to identify a pathogenic variant in
one of the MMR genes.
Universal screening of EC patients for LS has been
recommended by numerous experts and specialist societies.12
Such practice has already been adopted in several cancer
centers across the world.13–15 Proponents suggest a similar
proportion of EC is related to LS as seen in CRC.
Furthermore, there is evidence that EC is often the sentinel
cancer in women with LS.16 Therefore, a diagnosis of LS at the
time of EC diagnosis could afford earlier CRC surveillance
and achieve greater survival benefit. However, the true
proportion of EC associated with LS remains unclear.
Published proportions vary greatly, with estimates ranging
from 1% to around 10%.17,18 Such variation in estimates is in
part due to variable testing strategies employed across
different studies.
In this systematic review we sought to provide accurate
data estimating the outcomes of testing for LS in EC patients.
Specifically, we asked what proportion of EC patients would be
expected to be put forward for definitive germline
testing following initial tumor-based tests (namely IHC, MSI
with or without MLH1 promoter methylation analysis), and
secondly, what proportion of these would be confirmed Lynch
syndrome by next-generation sequencing (NGS). The results
of this study may be of benefit in informing the planning and
implementation of universal LS screening in EC patients.
MATERIALS AND METHODS
Search strategy and study identification
A systematic literature search devised by a specialist librarian,
following PRISMA guidelines,19 was undertaken. Medline,
Embase, Cochrane CENTRAL, and Web of Science were
searched. The gray literature and nonelectronic literature were
not included. Search terms were “colorectal neoplasms,
hereditary nonpolyposis” and “endometrial cancer” with
associated Medical Subject Headings (MeSH). In addition, a
secondary search was conducted using “Lynch syndrome” as a
multipurpose term and “endometrial cancer” as a MeSH term.
The search included all studies from source commencement
to the end of July 2018. Citation searching was utilized to
augment the initial results.
Studies found to have inconsistent results were excluded
after unanimous review and agreement between all authors.
Assessment of bias analysis was conducted by three reviewers
(N.A.J.R., D.B., and M.C.D.) independently using Review
Manager (RevMan) (Version 5.3. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014). Dis-
agreements were resolved by either unanimous agreement
after rereview or by the decision of the senior author (E.J.C.).
Selection criteria
The protocol for this systematic review was preregistered with
the PROSPERO database registration (ID: CRD42017081707)
and has been published.20 Only studies investigating LS in an
EC population were included. Initial searches were limited by
English language, human adults (>18 years), and female
subjects. Only studies that used either direct germline analysis
for pathogenic variants of MMR genes or proxy tumor-based
molecular diagnostic methods (IHC, MSI with or without
MLH1 promoter hypermethylation), or any combination of
these were included. Microsatellite instability-high (MSI-H)
was defined, where possible, as involving ≥30% of the
included microsatellite markers. An IHC positive result was
taken as loss of expression of one of the MMR proteins.
Pathogenic variants of MMR genes were defined as per the
authors’ analysis. To avoid double counting data, authors of
more than one study were contacted for clarification and/or
registry analysis was crosschecked. Where there was over-
lapping data, the larger study was included and the smaller
excluded. Only articles that contributed at least 15 partici-
pants were included.
Data extraction
The results from the initial search were combined. The titles and
abstracts were collated in a spreadsheet template downloaded
from http://libguides.sph.uth.tmc.edu/excel_workbook_home.
This is available from the authors on request. Duplicates were
removed with the use of Endnote X7 (Thompson Reuters, New
York, NY). All titles and abstracts where initially screened
independently by three authors (N.A.J.R., D.B., and M.C.D.).
Conflicts were resolved by unanimous agreement between the
three observers. Where unanimous agreement could not be
reached a senior author (E.J.C.) made the final decision. Those
studies identified as meeting the inclusion criteria underwent
full article review and data extraction. Those excluded at full
manuscript review are detailed in supplementary materials
appendix 1.
Baseline data extracted included type of study, selection
criteria, number of participants, country of origin, demo-
graphic data, type of initial screening method for LS, gold
standard test, pathogenic variant distribution, and pathology
distribution.
Statistical analysis
The primary outcome measure was the proportion of EC
patients who were identified as being likely LS (aberrant
MMR IHC expression, MSI-H with or without MLH1
promoter hypermethylation) or as carrying a germline
MMR pathogenic variant. The Freeman–Tukey (a double
arcsine transformation) transformed proportions of LS
positive EC patients were pooled using the inverse variance
heterogeneity model.21 To aid interpretation, all results were
presented after back transformation to natural proportions.
A quantification of heterogeneity across studies was
presented as an I2 score (with I2 score of 25%, 50%, and
75% representing low, moderate, and high levels of
heterogeneity respectively).22 All statistical analyses were
performed R, Version 3.3.1 (https://cran.r-project.org), using
the package “meta.”
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RESULTS
Search results
The combined search terms yielded 1119 articles. Primary
review of titles and abstracts identified 83 articles that
warranted full manuscript review. Of these, 56 studies met
the inclusion criteria. At data extraction and quality
assessment, three studies were removed due to incomplete
data (n= 1) (ref. 23), inconsistent presentation of results (n=
1) (ref. 24), or an inappropriate population (n= 1) (ref. 25)
(Fig. 1). Bias scores for each of the studies are outlined in
supplementary appendix 2.
Fifty-three papers were included for the final analyses.13–
15,17,18,26–73 These studies included 12,633 participants with
EC. The majority of studies were conducted in North America
(n= 33), with relatively small numbers carried out in Europe
(n= 6), Southeast Asia (n= 7), Australasia (n= 4), and South
America (n= 3). Twenty-three (43%) populations were
preselected by age, family history, or other clinical parameters
before analysis. Primary testing included MSI (n= 9), IHC (n
= 28), MSI and IHC (n= 13), or germline testing (n= 3).
Studies are summarized in Table 1.
All studies originated from specialist tertiary referral centers
or their biobanks. Histological features were reported in 20
papers. Type 1/endometrioid tumors constituted 79.3% of
tumors, consistent with the literature.74 There were insuffi-
cient data to describe the histological breakdown of tumors
diagnosed in women who were found to have abnormal
tumor triage or LS. From the studies that included age data (n
= 43), the median age of subjects tested was 59.5 years
(interquartile range [IQR:] 53–62).
Immunohistochemical analysis
In total, 42 papers reported the outcome of IHC analysis.
These studies include 10,683 participants, 10,460 with
completed IHC analysis. Of these, 2563 (25%) were found
to have absent expression of at least one of the MMR proteins
on IHC. This represents an overall proportion of 0.26
(confidence interval [CI] 95% 0.25–0.27, I2: 88%). When
preselected populations (cohorts restricted by clinical criteria
such as age at EC diagnosis) were excluded, a total of 7725
tumors underwent MMR IHC, of which 1948 (25%) were
MMR deficient (Fig. 3). Therefore, the proportion of
unselected ECs with MMR deficiency is 0.26 (95% CI
0.25–0.27, I2: 90%) and 0.25 (95% CI 0.23–0.27, I2: 85%) in
selected EC populations (Fig. 2).
Of note, only a proportion of studies tested for loss in all
four of the MMR proteins (23/42, 55%). MLH1-specific
outcome data were available for a total of 9306 study
participants. Of these, 1635 (18%) were found to be MLH1
protein deficient. When studies that preselected their
populations were excluded, the total number of subjects was
7176, of whom 1343 (19%) were MLH1 deficient. Full protein
specific data were available for 7385 subjects. Excluding
MLH1, deficiencies in MSH6 were the most commonly
recorded (n= 247/3%), followed by MSH2 (n= 211/3%) and
finally PMS2 (n= 153/2%). As MMR proteins are dimeric,
concurrent loss of both proteins within MutSα (MSH2/
MSH6) and MutLα (MLH1/PMS2) would be expected. For
MSH2, concurrent MSH6 loss was always seen across all
studies. For MLH1, PMS2 loss was also seen, with the
exception of one case. By contrast, isolated MSH6 was seen in
112 cases and isolated PMS2 loss in 13 cases. In studies with
no preselection and with complete protein analysis data there
were a total of 6104 study participants. Here the most
prevalent protein deficiency was in MSH6 (n= 165/3%)
followed by MSH2 (n= 153/3%) and PMS2 (n= 84/1%).
Of 5594 EC with MLH1 IHC and methylation analysis data,
1098 (20%) cases had MLH1 IHC loss. Of these, 963 (88%)
were found to be due to somatic hypermethylation of the
MLH1 promoter region. In unselected EC populations with
methylation analysis data, there were 4525 participants, the
tumors of whom showed MLH1 IHC loss in 960 (21%) cases.
Eight hundred forty-three (88%) were as a result of somatic
hypermethylation of the MLH1 promoter region. Therefore
the proportion of MLH1 IHC loss not attributed to somatic
hypermethylation of MLH1 was 0.11 (95% CI 0.10–0.13, I2:
78%) (supplementary appendix 4). From these data, there is
no significant difference between the proportion of ECs with
IHC MLH1 loss and normal methylation analysis according
to cohort selection.
Microsatellite instability analysis
MSI data were available for 4310 tumors, 2580 of which
were also tested by IHC. Of these, 1133 (26.3%) were MSI-
H. When studies that used preselective criteria were
excluded, the total number of participants was 2890, of
whom 768 were positive (26.6%) The overall proportion of
MSI-H ECs was 0.27 (CI 95% 0.25–0.28, I2: 71%). This was
0.27 (CI 95% 0.25–0.29, I2: 75%) and 0.26 (CI 95%
0.24–0.29, I2: 68%) for unselected and preselected popula-
tions, respectively (Fig. 3). The results of MLH1 methylation
analysis in conjunction with MSI testing are shown in
supplementary appendix 4.
There was no significant difference between the proportion
of positive test results if IHC or MSI was used as the initial
tumor triage (0.25 vs. 0.27 p value= 0.5 [Student's t test]).
Analysis of MSI proportions pre-2011 vs. post-2011 did not
find a significant difference (t test p value= 0.11).
Germline analysis
In total, 23 studies used some form of germline analysis to
establish a diagnosis of LS. There was a wide degree of
variation in the completeness of germline testing, with few
studies (n= 9) testing all those they intended to. Further-
more, 12 studies that used a tumor-based triage test did not
perform MLH1 promoter methylation testing. Two studies
failed to report the outcome of their MLH1 methylation
testing.14,54 The majority of these studies used another means
of excluding a proportion of their MLH1 IHC positive results,
for example a negative family history. Therefore, the
population that went on to have definitive germline analysis
is heterogeneous.
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-not Lynch syndrome (n=87)
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Wrong study type (n=353)
Study of etiology (n=233)
Other (n=231)
Duplicate (n=5)
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1119 titles and abstracts screened independently by 3 reviewers





























Selection criteria Primary test
56 full papers included. Data extracted independently by 2 reviewers.
Bias assessed independently by 3 reviewers
Fig. 1 Flowchart detailing study identification, study selection, and characteristics of included studies. IHC immunohistochemistry, MSI micro-
satellite instability.
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In total, 14,770 tumors underwent tumor-based triage
with IHC (n= 10,460) and/or MSI (n= 4310). Concurrent
testing with both IHC and MSI was sufficiently reported in
ten studies16,27,34,36,37,40,47,51,63,68 and enabled removal of
duplicates with positive concordant IHC and MSI data. Of
the remaining 14,293 tumors, 1133 were MSI-H and 2563
had aberrant IHC. Studies that reported MLH1-specific
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Heterogeneity: I2 = 90%, τ2 = 0.1557,p < 0.01












































































































































































































































































































































Fig. 2 Forest plot and meta-analysis of the proportion of endometrial tumors with mismatch repair deficiency by immunohistochemistry,
including those that did and did not preselect tumors for testing. CI confidence interval.
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(n= 5594) allowed further triage by removing tumors with
likely somatic MLH1 loss. In total, 1005 women were
eligible for and 700 women underwent germline testing for
Lynch syndrome following tumor-based triage. A total of
181 (26%) were positive. When studies that preselected their
population were excluded, the combined population was
5882, of whom, upon removal of methylated results, 821
(14%) were Lynch-like on the basis of their tumor analyses
and therefore should have undergone germline testing. A
total of 511 (62%) underwent testing and 150 (29%) were
positive. This represents an overall proportion of LS-related
pathogenic variants in those with positive tumor triage of
0.29 (CI 95% 0.25–0.33, I2: 83%). The same proportion in
unselected cases was 0.31 (CI 95% 0.26–0.35, I2: 84%) and
for selected 0.25 (CI 95% 0.18–0.33, I2: 79%) (Fig. 4).
Therefore, around 3% of ECs can be attributed to LS. The
gene breakdown from NGS is shown in supplementary
appendix 3.
Four studies, which examined unselected populations of EC,
had complete germline testing of cases suggestive of LS on the
basis of their tumor analysis. Focusing on these studies, 180
tumors were suggestive of LS of which 32 were found to have
a pathological variant in one of the MMR genes. This
represents a proportion of 0.21 (CI 95% 0.15–0.30, I2: 91%).
This is significantly fewer than reported in studies with
incomplete germline testing (p= 0.001) and suggests an
overreporting of pathological variants in studies that fail to
analyze all samples suggestive of LS from tumor triage. Only
three studies did direct germline analysis without tumor
triage. These studies were all highly selective, with Pennington
and colleagues testing only tumors of a serous histology,
which is not commonly associated with LS.75 Of 590 cancers
tested in these three studies, 27 (4.6%) were found to have a
germline pathological variant. If the data from Pennington are
removed, 6% of ECs were found to have pathogenic variants
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τ2 = 0.0756, p < 0.01
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Fig. 3 Forest plot and meta-analysis of the proportion of endometrial tumors showing microsatellite instability, including those that did and
did not preselect tumors for testing. CI confidence interval.
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appendix 5. Subgroup analysis of pre-2011 vs. post-2011
proportions of germline pathogenic variants found after
tumor triage was not significant (t test p value= 0.14).
Further subgroup analysis was carried out to explore the
relationship between potential confounding factors; these are
shown in supplementary appendix 5. Of note, those studies
that did not use a priori tumor-based triage, using instead
direct germline sequencing of all samples, found a higher
proportion of LS carriers (0.06); however, the number of
studies is limited (n= 3). In addition, limiting testing to
individuals less than 50 years yielded higher levels of MSI
(0.31) and aberrant IHC (0.28).
DISCUSSION
Here we present a systematic review and meta-analysis to
define the proportion of EC patients who test positive for LS.
This work includes data from 53 studies and 12,633
participants with EC who underwent IHC, MSI, methylation,
or germline analysis to diagnose LS. From these data, of 100
unselected cases of EC, approximately 3 people are estimated
to have LS, consistent with current literature.76,77 While this is
a modest percentage of positive tests, each diagnosis allows for
cascade testing of family members. It is estimated that 80% of
living first-degree relatives will accept LS screening.78 Newly
diagnosed LS patients are able to benefit from interventions to
prevent the development of other LS cancers, most notably
CRC. The results of this meta-analysis are summarized in
supplementary figure S12 showing the estimated outcome
from each stage of the LS diagnostic pathway.
Our results do not support the use of a particular tumor
triage method. The proportion of positive test results if IHC
or MSI was used as the initial tumor test (0.26 vs. 0.27 p value
= 0.5 [Student's t test]) was similar. This small difference
could be explained by the commonly used Bethesda panel
for the detection of MSI, which has only been validated
in CRC and not EC.79 In addition, MSH6 deficient EC
can be microsatellite low or stable.80 That said, IHC does
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Fig. 4 Forest plot and meta-analysis of the proportion of pathogenic variants in mismatch repairs (MMR) genes found in women with
endometrial tumors showing mismatch repair deficiency and/or microsatellite instability, including studies that did and did not preselect
women for testing. CI confidence interval.
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hypermethylation testing, given that it need only be applied to
MLH1 deficient tumors. In addition, germline analysis could
be limited to the gene(s) that corresponds to the protein lost;
this has potential cost saving implications.
Preselecting EC populations by age or clinical criteria did
not significantly change the proportion of positive IHC or
MSI results, although we did find higher proportions in these
subgroups. This is somewhat surprising, as preselected
populations would be expected to harbor more women with
LS. This may be partly explained by the later age of onset seen
with MSH6 pathological variants and truncating variants.81 In
other words, the application of age cutoffs reduces specificity
without a significant increase in sensitivity. However,
universal testing does seem to decrease the yield of pathogenic
variant carriers; this may arise from somatic events that lead
to false positives at the tumor triage stage. MLH1 methylation
is associated with increased age and so is more common in
older (unselected) populations.82 Subgroup analysis of studies
that did not use a tumor triage stage, instead using direct
germline sequencing, found a higher proportion of LS carriers
(0.06). This could suggest that tumor triage itself misses
potentially 50% of LS carriers. However, there were only three
studies in the subgroup analysis. In addition, one of the
studies preselected those who had germline testing on the
basis of age (<50 years). However, this finding should
encourage debate as to the application of NGS without
tumor-based triage in EC populations; even more so given the
decreasing cost of this technology.
Our work has several key strengths. Our conclusions are
based on the results of over 50 studies and 12,600 participants;
the search criteria were purposely broad as to capture the
maximum number of studies. During the screening phase,
three independent reviewers ensured the accuracy of study
selection and data capture. Therefore, the foundations of our
meta-analysis were robust. In addition, we have estimated the
proportions of positive results seen in IHC, MSI, MLH1
methylation, and germline testing with a high degree of
precision, as reflected in the narrow 95% confidence intervals
in our meta-analysis.
The heterogeneity across the studies included in our review
was high, and limits the strength of our conclusions. This is a
reflection of the varying quality and rigor of the included
studies, some of which had small numbers of participants, and
were subject to bias. The majority of studies used retrospective
cohorts. Furthermore, many studies failed to complete the
indicated testing in their cohorts, leading to ambiguity in their
conclusions. This is evidenced by the lower proportion of LS
pathological variants in those studies with complete germline
analysis of Lynch-like tumors versus those with partial
germline analysis (0.21 vs. 0.29). To allow for the pooling of
such heterogeneous data, studies were grouped according to
selection and diagnostic method. All studies that were
grouped reported the same endpoint.
Another potential weakness of this study is the evolution in
diagnostic technology over time. The included studies were
published between 1996 and 2017. During this time
diagnostic technology and guidelines have evolved signifi-
cantly. Although IHC based diagnostics has remained
relatively constant, MSI diagnostics has been informed by
the adoption of the Bethesda panel in 1998 and the
development of the more modern panels such as the
pentaplex and hexaplex panels, which became widely applied
to clinical practice after 2011.83 Even so, analysis of MSI
testing results pre- vs. post-2011 did not find a significant
difference (t test p value= 0.11). Only one study predates the
Bethesda guidelines. The area of germline diagnostics remains
innovative, but again analysis of pre- vs. post-2011 propor-
tions of germline pathogenic variants found after tumor triage
was not significant (t test p value= 0.14). Generalizability is
limited by the predominance of North American and
European populations in our study. Most took place in
insurance-based health-care systems, which impact negatively
on the uptake of genetic testing.84 Therefore, it could be that
the proportions are an underestimate due to reduced uptake
of testing, especially in high-risk groups such as the young or
those with a strong family history.
In summary, ours is the first meta-analysis to examine the
proportion of EC cases that are associated with LS. Different
tumor triage methods did not affect estimates of the
proportion of EC associated with LS, which remained
constant at around 3%. Our findings suggest that a similar
proportion of EC patients will test positive for LS as seen in
CRC LS screening. This supports the move toward the
introduction of universal screening for LS in EC.
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